Ovid Therapeutics Inc. (OVID)
- Previous Close
3.1500 - Open
3.1300 - Bid 2.9800 x 400
- Ask 3.0200 x 300
- Day's Range
2.9900 - 3.1400 - 52 Week Range
2.5700 - 4.1390 - Volume
109,642 - Avg. Volume
208,377 - Market Cap (intraday)
211.423M - Beta (5Y Monthly) 0.69
- PE Ratio (TTM)
-- - EPS (TTM)
-0.7400 - Earnings Date May 3, 2024 - May 7, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
7.33
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
www.ovidrx.comRecent News: OVID
Performance Overview: OVID
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: OVID
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: OVID
Valuation Measures
Market Cap
211.42M
Enterprise Value
121.59M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
538.78
Price/Book (mrq)
2.41
Enterprise Value/Revenue
310.42
Enterprise Value/EBITDA
-2.11
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-24.76%
Return on Equity (ttm)
-47.57%
Revenue (ttm)
391.69k
Net Income Avi to Common (ttm)
-52.34M
Diluted EPS (ttm)
-0.7400
Balance Sheet and Cash Flow
Total Cash (mrq)
105.83M
Total Debt/Equity (mrq)
18.23%
Levered Free Cash Flow (ttm)
-25.92M